Showing results (81-90 of 3,369) with videos related to

Sort By:
Pageof 337
ESC Heart Failure|July 26, 2017
A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohortJustin A Ezekowitz, Finlay A McAlister, Jonathan Howlett, et al.
ESC Heart Failure|July 26, 2017
Data privacy management and data quality monitoring in the German Centre for Cardiovascular Research's multicentre TranslatiOnal Registry for CardiomyopatHies (DZHK-TORCH)Thea Schwaneberg, Kerstin Weitmann, Andreas Dösch, et al.
ESC Heart Failure|August 1, 2017
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as predictors of survival after heart transplantationIgnacio M Seropian, Francisco J Romeo, Rodolfo Pizarro, et al.
ESC Heart Failure|July 29, 2017
High body mass index is a predictor of left ventricular reverse remodelling in heart failure with reduced ejection fractionArthur Cescau, Lucas N L Van Aelst, Mathilde Baudet, et al.
ESC Heart Failure|October 23, 2017
Chronic obstructive pulmonary disease and β-blocker treatment in Asian patients with heart failureYoshiaki Kubota, Wan Ting Tay, Kuniya Asai, et al.
ESC Heart Failure|July 15, 2022
Serum microRNAs are key predictors of long-term heart failure and cardiovascular death after myocardial infarctionLuis M Rincón, Macarena Rodríguez-Serrano, Elisa Conde, et al.
ESC Heart Failure|July 15, 2022
Peak O2 -pulse predicts exercise training-induced changes in peak V̇O2 in heart failure with preserved ejection fractionStephan Mueller, Bernhard Haller, Anna Feuerstein, et al.
ESC Heart Failure|July 15, 2022
Transgelin exacerbates pulmonary artery smooth muscle cell dysfunction in shunt-related pulmonary arterial hypertensionJing-Jing Zhou, Jian Yang, Li Li, et al.
ESC Heart Failure|July 29, 2022
Bioactive adrenomedullin for assessment of venous congestion in heart failureAnna Egerstedt, Tomasz Czuba, Kevin Bronton, et al.
ESC Heart Failure|June 23, 2018
Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH)Anne-Catherine Pouleur, Stefan Anker, Dulce Brito, et al.
Pageof 337